within Pharmacolibrary.Drugs.ATC.N;

model N05AD05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00011666666666666667,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 1800
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AD05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pipamperone is a typical antipsychotic drug belonging to the butyrophenone class. It is mainly used for the treatment of schizophrenia and other psychotic disorders, and has been utilized particularly in some European countries since the 1960s. The drug is not widely approved in the United States, but continues to be used in select countries for its sedative and antipsychotic effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as estimated for a healthy adult population based on available literature and data summaries, not direct clinical PK study.</p><h4>References</h4><ol><li><p>Potgieter, GE, et al., &amp; Sewarte-Ross, G (2002). Pharmacokinetics of pipamperone from three different tablet formulations. <i>Arzneimittel-Forschung</i> 52(6) 430–434. DOI:<a href=\"https://doi.org/10.1055/s-0031-1299910\">10.1055/s-0031-1299910</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12109042/\">https://pubmed.ncbi.nlm.nih.gov/12109042</a></p></li><li><p>Janssen, PA, &amp; Awouters, FH (1994). Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone. <i>Arzneimittel-Forschung</i> 44(3) 269–277. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7514873/\">https://pubmed.ncbi.nlm.nih.gov/7514873</a></p></li><li><p>Patteet, L, et al., &amp; Neels, H (2016). Determination of Common Antipsychotics in Quantisal-Collected Oral Fluid by UHPLC-MS/MS: Method Validation and Applicability for Therapeutic Drug Monitoring. <i>Therapeutic drug monitoring</i> 38(1) 87–97. DOI:<a href=\"https://doi.org/10.1097/FTD.0000000000000242\">10.1097/FTD.0000000000000242</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26349083/\">https://pubmed.ncbi.nlm.nih.gov/26349083</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AD05;
